undefined

undefined

Home page

Ibuprofen Sustained-Release Capsules Approved for Marketing: Analgesic and Anti-inflammatory Portfolio Further Expanded

Ibuprofen Sustained-Release Capsules Approved for Marketing: Analgesic and Anti-inflammatory Portfolio Further Expanded

Recently, Ibuprofen Sustained-Release Capsules of Jiudian Pharmaceutical officially received a drug registration approval from the National Medical Products Administration (NMPA) and successfully passed the generic drug consistency evaluation. As a product on the National Essential Medicines List, a Class B product under the National Reimbursement Drug List, a product included in national volume-based procurement, and a nonsteroidal anti-inflammatory drug recommended as first-line therapy in clinical practice, its successful launch marks a further expansion of Jiudian Pharmaceutical's product portfolio in analgesia and anti-inflammation.

21

2026

/

09

Lacidipine Tablets Approved for Marketing: Jiudian Adds Another Major Product in the Treatment of Hypertension

Lacidipine Tablets Approved for Marketing: Jiudian Adds Another Major Product in the Treatment of Hypertension

Recently, Lacidipine Tablets of Jiudian Pharmaceutical officially received a drug registration approval from the National Medical Products Administration (NMPA) and successfully passed the generic drug consistency evaluation. As a third-generation, highly lipophilic, long-acting calcium channel blocker (CCB), the successful approval of this product marks an important step by Jiudian Pharmaceutical in the treatment of cardiovascular and cerebrovascular diseases and further enriches the company's product pipeline.

17

2026

/

09

Jiudian Pharmaceutical Listed Again among Hunan's Top 100 Manufacturing Enterprises, with Its Ranking Continuing to Rise

Jiudian Pharmaceutical Listed Again among Hunan's Top 100 Manufacturing Enterprises, with Its Ranking Continuing to Rise

On June 5, the Conference on Advancing the Building of an Advanced Manufacturing Highland in Hunan Province was held in Changsha. The 2025 Hunan Top 100 Enterprises list, the 2025 Hunan Top 100 Manufacturing Enterprises list, and other rankings were officially released at the conference. On the strength of its manufacturing capability and operating performance, Jiudian Pharmaceutical was named to the Top 100 Manufacturing Enterprises in Hunan, ranking 75th, and maintained its momentum of consecutive listings with a steady rise in ranking.

15

2026

/

09

Jiudian Hongyang Pharmaceutical Excipient Kaolin Approved for Marketing

Jiudian Hongyang Pharmaceutical Excipient Kaolin Approved for Marketing

09

2026

/

09

Jiudian Hongyang Pharmaceutical Excipient Docusate Sodium/Sodium Benzoate Approved for Marketing

Jiudian Hongyang Pharmaceutical Excipient Docusate Sodium/Sodium Benzoate Approved for Marketing

Good news has recently arrived. The pharmaceutical excipient docusate sodium/sodium benzoate (F20250000020) of Jiudian Hongyang has had its registration status changed to "A" at the Center for Drug Evaluation (CDE) of the National Medical Products Administration. It has been successfully approved for marketing and is qualified for compliant commercial supply.

01

2026

/

09

Jiudian Pharmaceutical's Flurbiprofen Cataplasms Approved, Adding a Major Transdermal Drug Delivery Product

Jiudian Pharmaceutical's Flurbiprofen Cataplasms Approved, Adding a Major Transdermal Drug Delivery Product

Jiudian Pharmaceutical recently announced that its flurbiprofen Cataplasms has officially received a drug registration approval from the National Medical Products Administration (NMPA) and has successfully passed the generic drug consistency evaluation. As one of the leading topical patch products in China, this approval marks a pivotal step in Jiudian's strategic goal of establishing itself as a leader in the domestic transdermal drug delivery field.

30

2026

/

05

Jiudian Hongyang Named "Outstanding Talent-Attracting Enterprise," Driving New-Quality Productivity Leap with Talent Engine

Jiudian Hongyang Named "Outstanding Talent-Attracting Enterprise," Driving New-Quality Productivity Leap with Talent Engine

On the morning of May 23, the Wangcheng Economic and Technological Development Zone witnessed a gathering of bright young minds at the College Student Innovation and Entrepreneurship Base, as the zone held its talent policy announcement and 2026 industrial talent recruitment event for urgently needed professionals. Jiudian Hongyang was invited to attend and was honored with the "Outstanding Talent-Attracting Enterprise" award for 2025 at the event, with Director Wang from the company's Administration Department accepting the award on behalf of the enterprise.

26

2026

/

05

Jiudian Co-sponsors the First Integrated Chinese and Western Medicine Pain Professional Committee Conference

Jiudian Co-sponsors the First Integrated Chinese and Western Medicine Pain Professional Committee Conference

On May 23, the inaugural meeting of the Integrated Chinese and Western Medicine Pain Professional Committee was held in Changsha. The conference was hosted by the Hunan Society of Integrative Medicine and co-sponsored by Jiudian Pharmaceutical, with a focus on implementing the concepts of integrative medicine, promoting the standardized development of integrated Chinese and Western medicine pain diagnosis and treatment, and fostering academic collaborative innovation. Jiudian Pharmaceutical showcased its flagship products including Jiudian® Daiwenjiu Plaster and Jiudian® Ketoprofen Gel, setting up a dedicated exhibition booth featuring product displays, on-site trials, and academic exchanges, providing attending experts and clinicians with a comprehensive view of the clinical value and application advantages of the two core topical products.

25

2026

/

05

< 1 2 3 4...17 >

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China TEL. 0086-731-88220222

1

Business license

Powered by：CEglobal Privacy policy